Dr. David Gamm examines the eyes of Gavina Zimbric, 11, of Waterloo, at UW Health’s University Station Clinic. Gamm, a pediatric ophthalmologist, is using stem cells to try to develop cell therapies for blinding disorders. He’s one of about 100 faculty researchers at UW-Madison studying stem cells, 20 years after campus scientist James Thomson announced he first grew human embryonic stem cells in the lab. Gamm performed surgery on Gavina, who had strabismus or crossed eyes. Apps, S. (Photographer). (2018, November 29). Madison, WI: Wisconsin State Journal.
Two decades after University of Wisconsin-Madison’s biologist James Thomson’s unprecedented achievement in lab-grown human embryonic cells, pediatric ophthalmologist David Gamm is fighting blindness through generating ‘spare parts’ of human eyes, on the foundation of Thomson’s leading stem-cell works.
As a pediatric ophthalmologist, Professor Gamm understands how devastating it is to a family when the child is hopelessly losing their sight due to genetic disorders of the eye. Frustrated with the fact that human eye is unable to reproduce photoreceptors, the critical light-sensing cells to one’s vision, and later inspired by Dr. Thomson’s discovery in stem-cell research, Dr. Gamm started an almost-decade-long trial on realizing lab-grown photoreceptors.
“I learned about UW-Madison researcher James Thomson’s pioneering work in stem cells. We figured there must be a way to take these very undifferentiated stem cells, which are kind of little pieces of human-cell clay, and mold them into spare parts for the retina,” said Gamm in an interview with Wisconsin State Journal in November 2018.
Nearly ten years later, Dr. Gamm and his team have successfully developed methods to produce crucial human eye tissues including photoreceptors and even whole human retinas in laboratories. Along with another project focuses on partial thickness cornea transplants, which are used to repair diseased tissue that clouds light entering the eye. Neal Barney, a UW–Madison ophthalmologist, is developing a high-tech, synthetic carrier to deliver a thin cadaver-derived corneal tissue during surgery. “These ultra-thin tissues can fold up like wet tissue paper during surgery,” Murphy says. “The goal is to develop and manufacture a membrane to transport this tissue to the patient and hold it in place until it grafts, and then dissolve over time.” These discoveries bring lights to human vision loss.
Yet having practical sources of new human photoreceptors is only the first half of the mission. A much more challenging part of the battle awaits, for it is still uncertain whether the human eye can well adapt regenerative cells. “If the downstream retinal circuit is a mess, putting fresh, new cells in there isn’t going to be of much help. In other words, a new light bulb is of no use if the socket wires are cut,” Gamm explains. “Fortunately, the socket wires appear to be in reasonable working order in many patients with photoreceptor degenerations.”